^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial
Published date:
09/01/2023
Excerpt:
At data cutoff (March 3, 2023), median follow-up was 18·1 months (IQR 12·7–20·4). The primary endpoint was reached, with 25 (71%; 95% CI 54–85) of 35 patients progression free at 6 months. Nine (26%) of 35 patients had disease progression and one (3%) patient died; the death was unrelated to treatment...Regorafenib can be safely combined with nivolumab and chemotherapy and showed promising activity in HER2-negative metastatic oesophagogastric cancer.
Secondary therapy:
FOLFOX
DOI:
10.1016/S1470-2045(23)00358-3
Trial ID:
Source:
Title:
1227P - Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC)
Published date:
09/05/2022
Excerpt:
Patients (pts) with HER2 negative, untreated, metastatic EG adenocarcinoma, irrespective of PD-L1 status, received REGO (80 mg daily), NIVO (240 mg every 2 weeks), plus FOLFOX....90% of the 29 pts with RECIST 1.1 measurable disease had tumor regression (-5% to -100%). The ORR was 62% (16 PR, 2 CR) in the entire cohort, 62% ORR in pts with CPS<5 (13 of 21), and 63% ORR in pts with CPS>5 (5 of 8)....The majority of patients had a response, irrespective of PDL1 status, with no new safety signals.
Secondary therapy:
FOLFOX
Trial ID:
